▲ +170.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pluristem Therapeutics in the last 3 months. The average price target is $9.88, with a high forecast of $12.50 and a low forecast of $6.00. The average price target represents a 170.55% upside from the last price of $3.65.
The current consensus among 4 polled investment analysts is to buy stock in Pluristem Therapeutics. This Buy consensus rating has held steady for over two years.
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.